Novus Biologicals products are now on bio-techne.com

Recombinant Human VEGFR2/KDR Fc Chimera Protein, CF

Images

 
There are currently no images for VEGFR2/KDR/Flk-1 (357-KD/CF).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Bioactivity
Format
Carrier-Free

Order Details

View Available Formulations
Catalog# & Formulation Size Price
Novus Biologicals is part of Bio-Techne

Shop this product on bio-techne.com

Recombinant Human VEGFR2/KDR Fc Chimera Protein, CF Summary

Details of Functionality
Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 10-40 ng/mL in the presence of 10 ng/mL recombinant human VEGF165.
Source
Mouse myeloma cell line, NS0-derived human VEGFR2/KDR/Flk-1 protein
Human VEGFR2
(Ala20-Glu764)
Accession # AAC16450
IEGRMD Human IgG1
(Pro100-Lys330)
6-His tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Ala20
Structure / Form
Disulfide-linked homodimer
Protein/Peptide Type
Recombinant Proteins
Gene
KDR
Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Dilutions
  • Bioactivity
Theoretical MW
110 kDa (monomer).
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
160-170 kDa, reducing conditions
Publications
Read Publications using
357-KD/CF in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS.
Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VEGFR2/KDR Fc Chimera Protein, CF

  • CD309 antigen
  • CD309
  • EC 2.7.10
  • EC 2.7.10.1
  • Fetal liver kinase 1
  • fetal liver kinase-1
  • Flk1
  • Flk-1
  • FLK1tyrosine kinase growth factor receptor
  • KDR
  • kinase insert domain receptor (a type III receptor tyrosine kinase)
  • Kinase insert domain receptor
  • KRD1
  • Ly73
  • Protein-tyrosine kinase receptor flk-1
  • soluble VEGFR2
  • vascular endothelial growth factor receptor 2
  • VEGF R2
  • VEGFR
  • VEGFR2
  • VEGFR-2

Background

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

VEGFR2 cDNA encodes a 1356 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 745 aa residue extracellular domain, a 25 aa residue transmembrane domain and a 567 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Customers Who Viewed This Item Also Viewed...

DVE00
Species: Hu
Applications: ELISA
AF321
Species: Hu
Applications: Block, CyTOF-ready, Flow, IHC, WB
AF231
Species: Hu
Applications: CyTOF-ready, Dual ISH-IHC, ELISA(Cap), ELISA(Det), ELISA(Sta), Flow, ICC, IHC, IP, Simple Western, WB
AF4117
Species: Rt
Applications: IHC, WB
AF743
Species: Mu
Applications: CyTOF-ready, Flow, WB
AF3628
Species: Hu, Mu, Rt
Applications: CyTOF-ready, Flow, ICC, IHC, Simple Western, WB
AF887
Species: Hu, Mu, Rt
Applications: CyTOF-ready, IHC, ICFlow, Simple Western, WB
NB110-41083
Species: Hu
Applications: ChIP, ELISA, ICC/IF, WB
AF1356
Species: Hu, Mu
Applications: CyTOF-ready, Dual ISH-IHC, Flow, IHC, Simple Western, WB
DPG00
Species: Hu
Applications: ELISA
AF566
Species: Mu, Rt
Applications: Block, CyTOF-ready, Flow, IHC, WB
NBP2-22203
Species: Hu, Pm, Mu, Rt
Applications: ELISA, Flow, ICC/IF, IHC, IHC-P, WB
DVEC00
Species: Hu
Applications: ELISA
233-FB
Species: Hu
Applications: BA
AF1042
Species: Mu
Applications: Dual ISH-IHC, IHC, WB
357-KD/CF
Species: Hu
Applications: Bioactivity

Publications for VEGFR2/KDR/Flk-1 (357-KD/CF)(40)

We have publications tested in 5 confirmed species: Human, Mouse, Chick, N/A, Porcine.

We have publications tested in 11 applications: Binding Assay, Bioassay, ELISA, ELISA (Standard), ELISA Capture, Enzyme Assay, Functional ELISA, IHC, In Vivo, SPR, Surface Plasmon Resonance.


Filter By Application
Binding Assay
(3)
Bioassay
(25)
ELISA
(1)
ELISA (Standard)
(1)
ELISA Capture
(1)
Enzyme Assay
(1)
Functional ELISA
(1)
IHC
(1)
In Vivo
(2)
SPR
(1)
Surface Plasmon Resonance
(4)
All Applications
Filter By Species
Human
(25)
Mouse
(5)
Chick
(1)
N/A
(1)
Porcine
(3)
All Species
Showing Publications 1 - 10 of 40. Show All 40 Publications.
Publications using 357-KD/CF Applications Species
M Chuai, G Serrano Ná, M Serra, L Mahadevan, CJ Weijer Reconstruction of distinct vertebrate gastrulation modes via modulation of key cell behaviors in the chick embryo Science Advances, 2023-01-04;9(1):eabn5429. 2023-01-04 [PMID: 36598979] (Bioassay, Chick) Bioassay Chick
AV Yagolovich, AA Artykov, AA Isakova, YV Vorontsova, DA Dolgikh, MP Kirpichnik, ME Gasparian Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor Specificity International Journal of Molecular Sciences, 2022-05-24;23(11):. 2022-05-24 [PMID: 35682540] (ELISA Capture, Human) ELISA Capture Human
L Lu, H Chen, L Wang, L Zhao, Y Cheng, A Wang, F Wang, X Zhang A Dual Receptor Targeting- and BBB Penetrating- Peptide Functionalized Polyethyleneimine Nanocomplex for Secretory Endostatin Gene Delivery to Malignant Glioma Int J Nanomedicine, 2020-11-12;15(0):8875-8892. 2020-11-12 [PMID: 33209022] (SPR, Human) SPR Human
K Fujiwara, S Sasawatari, S Nakai, K Imaeda, S Nagai, Y Matsuno, K Hatanaka, Y Hatanaka, S Takenaka, N Okada Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting Cancers) Therapy for Soft Tissue Sarcoma Patients Cancers, 2020-09-23;12(10):. 2020-09-23 [PMID: 32977646] (Bioassay, Human) Bioassay Human
SB Mamer, A Wittenkell, PI Imoukhuede VEGF-A splice variants bind VEGFRs with differential affinities Sci Rep, 2020-09-02;10(1):14413. 2020-09-02 [PMID: 32879419] (Bioassay, Surface Plasmon Resonance, Human, N/A) Bioassay, Surface Plasmon Resonance Human, N/A
H Seo, H Masuda, K Asagoshi, T Uchiki, S Kawata, G Sasaki, T Yabuki, S Miyai, N Takahashi, SI Hashimoto, A Sawada, A Takaiwa, C Koyama, K Tamai, K Kurosawa, KY Lin, K Ohta, Y Nakazaki Streamlined human antibody generation and optimization by exploiting designed immunoglobulin loci in a B cell line Cell. Mol. Immunol., 2020-05-26;0(0):. 2020-05-26 [PMID: 32457406] (Mouse) Mouse
F Njau, N Shushakova, H Schenk, VC Wulfmeyer, R Bollin, J Menne, H Haller Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice PLoS ONE, 2020-01-14;15(1):e0218494. 2020-01-14 [PMID: 31935212] (Bioassay, Human) Bioassay Human
Ö Uslu, J Herold, S M Kanse VEGF-A-Cleavage by FSAP and Inhibition of Neo-Vascularization Cells, 2019-11-06;8(11):. 2019-11-06 [PMID: 31698750] (Bioassay, Human) Bioassay Human
JA Buczek-Tho, CB Rich, MA Nugent Hypoxia Induced Heparan Sulfate Primes the Extracellular Matrix for Endothelial Cell Recruitment by Facilitating VEGF-Fibronectin Interactions Int J Mol Sci, 2019-10-12;20(20):. 2019-10-12 [PMID: 31614727] (Bioassay, Human) Bioassay Human
Y Zhang, L Yong, Y Luo, X Ding, D Xu, X Gao, S Yan, Q Wang, J Luo, D Pu, J Zou Enhancement of HIFU ablation by sonosensitizer-loading liquid fluorocarbon nanoparticles with pre-targeting in a mouse model Sci Rep, 2019-05-06;9(1):6982. 2019-05-06 [PMID: 31061456] (Bioassay, Human) Bioassay Human
Show All 40 Publications.

Reviews for VEGFR2/KDR/Flk-1 (357-KD/CF) (0)

There are no reviews for VEGFR2/KDR/Flk-1 (357-KD/CF). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for VEGFR2/KDR/Flk-1 (357-KD/CF) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional VEGFR2/KDR/Flk-1 Products

Blogs on VEGFR2/KDR/Flk-1

There are no specific blogs for VEGFR2/KDR/Flk-1, but you can read our latest blog posts.
Read our latest blog and use the new citation tool on bio-techne.com

Customers Who Bought This Also Bought

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human VEGFR2/KDR Fc Chimera Protein, CF and receive a gift card or discount.

Bioinformatics

Gene Symbol KDR
Uniprot